250 related articles for article (PubMed ID: 21978487)
1. Feasibility of home-based automated Parkinson's disease motor assessment.
Mera TO; Heldman DA; Espay AJ; Payne M; Giuffrida JP
J Neurosci Methods; 2012 Jan; 203(1):152-6. PubMed ID: 21978487
[TBL] [Abstract][Full Text] [Related]
2. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
Li MH; Mestre TA; Fox SH; Taati B
J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
[TBL] [Abstract][Full Text] [Related]
3. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
4. A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor.
Khodakarami H; Shokouhi N; Horne M
J Neuroeng Rehabil; 2021 Jul; 18(1):116. PubMed ID: 34271971
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
Mera TO; Burack MA; Giuffrida JP
Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():154-7. PubMed ID: 23365855
[TBL] [Abstract][Full Text] [Related]
6. Quantitative motor assessment of dyskinesias in Parkinson's disease.
Schaeffer E; Maetzler W; Liepelt-Scarfone I; Sass C; Reilmann R; Berg D
J Neural Transm (Vienna); 2015 Sep; 122(9):1271-8. PubMed ID: 25712401
[TBL] [Abstract][Full Text] [Related]
7. Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease.
Mera TO; Burack MA; Giuffrida JP
J Parkinsons Dis; 2013 Jan; 3(3):399-407. PubMed ID: 23948993
[TBL] [Abstract][Full Text] [Related]
8. High-resolution tracking of motor disorders in Parkinson's disease during unconstrained activity.
Roy SH; Cole BT; Gilmore LD; De Luca CJ; Thomas CA; Saint-Hilaire MM; Nawab SH
Mov Disord; 2013 Jul; 28(8):1080-7. PubMed ID: 23520058
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of spirography features for objective assessment of motor function in Parkinson's disease.
Sadikov A; Groznik V; Možina M; Žabkar J; Nyholm D; Memedi M; Bratko I; Georgiev D
Artif Intell Med; 2017 Sep; 81():54-62. PubMed ID: 28416144
[TBL] [Abstract][Full Text] [Related]
10. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
[TBL] [Abstract][Full Text] [Related]
11. Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect.
Ramsperger R; Meckler S; Heger T; van Uem J; Hucker S; Braatz U; Graessner H; Berg D; Manoli Y; Serrano JA; Ferreira JJ; Hobert MA; Maetzler W;
Parkinsonism Relat Disord; 2016 May; 26():41-6. PubMed ID: 26952699
[TBL] [Abstract][Full Text] [Related]
12. Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors.
Pulliam CL; Heldman DA; Brokaw EB; Mera TO; Mari ZK; Burack MA
IEEE Trans Biomed Eng; 2018 Jan; 65(1):159-164. PubMed ID: 28459677
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
[TBL] [Abstract][Full Text] [Related]
15. Prospective study on cost-effectiveness of home-based motor assessment in Parkinson's disease.
Cubo E; Mariscal N; Solano B; Becerra V; Armesto D; Calvo S; Arribas J; Seco J; Martinez A; Zorrilla L; Heldman D
J Telemed Telecare; 2017 Feb; 23(2):328-338. PubMed ID: 27000142
[TBL] [Abstract][Full Text] [Related]
16. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
[TBL] [Abstract][Full Text] [Related]
17. Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
Lopane G; Mellone S; Chiari L; Cortelli P; Calandra-Buonaura G; Contin M
Mov Disord; 2015 Aug; 30(9):1267-71. PubMed ID: 26179817
[TBL] [Abstract][Full Text] [Related]
18. Detection of Levodopa Induced Dyskinesia in Parkinson's Disease patients based on activity classification.
Jalloul N; Porée F; Viardot G; L'Hostis P; Carrault G
Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():5134-7. PubMed ID: 26737447
[TBL] [Abstract][Full Text] [Related]
19. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
